ADC Therapeutics is preparing to reveal fresh clinical insights on its ongoing LOTIS-7 Phase 1b trial. The company will host a conference call and live webcast on December 3, 2025, at 8:00 a.m. EST.
The trial evaluates the safety and efficacy of ZYNLONTA®, the company’s flagship ADC, in combination with the bispecific antibody glofitamab (COLUMVI®) for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
What the Announcement Covers?
- Trial Status: The LOTIS-7 study is an open-label Phase 1b trial assessing this dual-agent approach in heavily pre-treated lymphoma patients.
- Accessing the Update: Participants can join through a guided registration link.
A toll-free dial-in number (1-800-836-8184) is available for callers in North America and Canada. ADC Therapeutics recommends joining ten minutes early. - Replay Details: A full webcast will be hosted in the Events and Presentations section of the company’s Investor page. An archived version will remain available for 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a global leader in antibody-drug conjugates. The company focuses on targeted therapies that deliver potent cytotoxics directly to cancer cells.
Key Assets
- ZYNLONTA (loncastuximab tesirine-lpyl)
- A CD19-directed ADC.
- Holds FDA accelerated approval.
- Received conditional approval from the European Commission.
- Indicated for r/r DLBCL after two or more lines of systemic therapy.
- Being evaluated in combination regimens and earlier treatment settings. - Next-Generation PSMA-Targeting ADC
- Designed using a differentiated exatecan-based payload.
- Uses a novel hydrophilic linker.
- Undergoing IND-enabling activities.
Global Footprint
ADC Therapeutics operates from Lausanne (Biopôle), Switzerland, with teams in London and New Jersey. The company manages end-to-end capabilities spanning research, clinical development, manufacturing and commercialization.
